全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2019.18.1059
Keywords: A Case Report,Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients,Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition,Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer,Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma,Research Progress on Potential Therapeutic Targets of Small Cell Lung Cancer,Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer,Research Advances in Molecular Regulatory Mechanism of Chordoma,Long-term Remission of Advanced Adrenocortical Carcinoma with KDR Gene Mutation Treated with Apatinib Mesylate: A Case Report,Correlation Between Ki67 Expression and 18F-FDG PET/CT SUVmax in Patient with Diffuse Large B-cell Lymphoma and Their Application in Therapeutic Effect Evaluation
Full-Text Cite this paper Add to My Lib
摘要 血管新生在肿瘤的生长以及转移过程中发挥重要作用，其中血管内皮生长因子受体2（VEGFR2）是关键的调控因子。甲磺酸阿帕替尼是我国历经十年研制成功的一种小分子酪氨酸激酶抑制剂，可高特异性结合VEGFR2。目前阿帕替尼单药在临床已成功应用于晚期胃癌、非小细胞肺癌、乳腺癌等常见肿瘤的治疗。阿帕替尼与其他抗肿瘤疗法的联用往往可以达到增加药效、减少不良反应的效果。本文主要针对目前报道过的临床实验以及基础研究来简要说明阿帕替尼与其他药物联合治疗用于不同肿瘤的治疗效果以及作用机制
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
